Mersana Therapeutics, Inc. Common Stock
MRSN
MRSN: Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
moreShow MRSN Financials
Recent trades of MRSN by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by MRSN's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Pyrrolobenzodiazepine antibody conjugates May. 02, 2023
-
Patent Title: Compositions and methods for predicting response to napi2b-targeted therapy Mar. 07, 2023
-
Patent Title: Monoclonal antibodies against her2 epitope and methods of use thereof Dec. 06, 2022
-
Patent Title: Napi2b-targeted polymer antibody-drug conjugates and methods of use thereof Aug. 09, 2022
-
Patent Title: Sting agonist compounds and methods of use Oct. 26, 2021
-
Patent Title: Peptide-containing linkers for antibody-drug conjugates Oct. 05, 2021
-
Patent Title: Napi2b-targeted antibody-drug conjugates and methods of use thereof Mar. 16, 2021
-
Patent Title: Pyrrolobenzodiazepines and conjugates thereof May. 26, 2020
-
Patent Title: Protein-polymer-drug conjugates Jan. 21, 2020
-
Patent Title: Pyrrolobenzodiazepines and conjugates thereof Jan. 07, 2020
-
Patent Title: Auristatin compounds and conjugates thereof Mar. 12, 2019
-
Patent Title: Pyrrolobenzodiazepines and conjugates thereof Dec. 04, 2018
-
Patent Title: Protein-polymer-drug conjugates Apr. 17, 2018
-
Patent Title: Hydroxyl-polymer-drug-protein conjugates Jan. 23, 2018
-
Patent Title: Protein-polymer-drug conjugates Dec. 26, 2017
-
Patent Title: Protein-polymer-drug conjugates and methods of using same Nov. 07, 2017
-
Patent Title: Protein-polymer-drug conjugates Sep. 26, 2017
-
Patent Title: Monoclonal antibodies against her2 epitope and methods of use thereof Aug. 22, 2017
-
Patent Title: Monoclonal antibodies against her2 epitope and methods of use thereof Jan. 31, 2017
-
Patent Title: Protein-polymer-drug conjugates Feb. 09, 2016
-
Patent Title: Protein-polymer-drug conjugates Sep. 29, 2015
-
Patent Title: Protein-polymer-drug conjugates Sep. 02, 2014
-
Patent Title: Protein-polymer-drug conjugates Aug. 26, 2014
-
Patent Title: Auristatin compounds and conjugates thereof Aug. 19, 2014
-
Patent Title: Protein-polymer-drug conjugates Apr. 01, 2014
-
Patent Title: Polyal drug conjugates comprising variable rate-releasing linkers Sep. 03, 2013
-
Patent Title: Pharmaceutical formulations of biodegradable biocompatible camptothecin-polymer conjugates Jul. 23, 2013
-
Patent Title: Biocompatible biodegradable fumagillin analog conjugates Mar. 19, 2013
-
Patent Title: Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof Jan. 08, 2013
Federal grants, loans, and purchases
Followers on MRSN's company Twitter account
Number of mentions of MRSN in WallStreetBets Daily Discussion
Recent insights relating to MRSN
Recent picks made for MRSN stock on CNBC
ETFs with the largest estimated holdings in MRSN
Flights by private jets registered to MRSN